Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced that Shanghai Concord Cancer Hospital officially started construction on September 20.

Shanghai Concord Cancer Hospital is a "Level III" specialty cancer hospital project invested by Concord Medical. Shanghai Concord Cancer Hospital is located in Shanghai New Hongqiao International Medical Center, which is a cooperation project between the National Health and Family Planning Commission and the Shanghai Municipal Government and one of 13 approved national tourism medical demonstration bases in 2017. With a total construction area of about 160,000 square meters, the project will be equipped with 400 beds and high-end, large-scale medical equipment, including proton therapy equipment. With a total investment amount of more than RMB 2 billion, Shanghai Concord Cancer Hospital is expected to be the largest Sino-foreign joint venture tumor specialty hospital with the highest investment in Shanghai to date.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "I am pleased to see that, after years of efforts, Shanghai Concord Cancer hospital has started construction. The commencement of this project is an important milestone in the overall strategic development of Concord Medical. The hospital will rely on the University of Texas MD Anderson Cancer Center's management and technical advantages, and strives to be Asia's most advanced cancer hospital. We will make every effort to ensure that the project is completed on time, with emphasis on quality and safety. I believe that the completion of the Shanghai Concord Cancer Hospital will not only promote the development of cancer therapy in China, but will also help Chinese cancer patients in their recovery."

About Concord Medical

Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of June 30, 2017, the Company operated a network of 60 centers with 41 hospital partners that spanned 34 cities and 19 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.